Malarone

Atovaquone/Proguanil, the active ingredient in Malarone, is an antimalarial presented as an oral tablet. It combines atovaquone and proguanil to prevent and treat malaria caused by Plasmodium species in travelers and residents of endemic regions.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including government health agencies and NGOs, providing reliable access to quality‑assured antimalarial therapy for global health programmes.

Malarone is an antimalarial tablet that acts on the Plasmodium parasite to prevent infection and treat disease.

- Malaria prophylaxis: prevents malaria in travelers to endemic areas. - Acute uncomplicated P. falciparum malaria: treats infection in patients with confirmed disease. - Chloroquine‑resistant malaria: provides an effective alternative when resistance limits other therapies.

Malarone may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient pain often reported. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose stools occurring during treatment. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: signs of liver injury including jaundice. - Hemolysis in G6PD‑deficient patients: rapid breakdown of red blood cells. - Anaphylaxis: life‑threatening allergic response. - Psychiatric disturbances: rare mood or anxiety changes.

Before using Malarone, consider the following safety measures.

- Pregnancy: consult a healthcare provider as safety data are limited. - Renal impairment: dose adjustment may be required for reduced kidney function. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant CYP450‑affecting drugs: monitor for altered drug levels. - Known hypersensitivity: avoid if allergic to atovaquone, proguanil, or excipients. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Malarone can interact with other medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Rifampin: markedly reduces atovaquone plasma concentrations, compromising efficacy. - Protease inhibitors (e.g., ritonavir): may lower atovaquone levels, diminishing therapeutic effect. - Cimetidine: can increase proguanil exposure, raising risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Phenytoin: can decrease atovaquone levels, potentially reducing effectiveness. - Ketoconazole: may increase atovaquone concentrations, necessitating observation for side effects.